BridgeMD
New treatment option for Statin
Official title Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population
ClinicalTrials.gov ID: NCT05725096
What this study is testing
- What it's testing
- The primary objective of this study is to determine whether coronary computed tomography angiography (CCTA) -based coronary heart disease(CHD) prevention strategy improves lipid-lowering treatment and cardiovascular risk factor control compared with traditional CHD prevention strategy, guided by a cardiovascular risk score.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 69
You may be able to join if
- Nanjing residents who have no plans to leave in the next 5 years
- Aged from 40 to 69 years
- Free of any known clinically cardiovascular disease Able to comprehend and sign an informed consent form
You likely can't join if
- Serious liver dysfunction, defined as AST or ALT \> 3 times the normal upper limit
- Chronic kidney disease (CKD) \> stage 4, defined as eGFR \< 30 ml/min/1.73 m2
- Prior CCTA or invasive coronary angiography within the last 5 years
- Any contraindications for CCTA
- Previous use of statin or non-statin lipid-lowering medication (such as ezetimibe, PCSK9 inhibitor and XueZhiKang)
- Life expectancy \< 3 years
See the full eligibility criteria
- Nanjing residents who have no plans to leave in the next 5 years
- Aged from 40 to 69 years
- Free of any known clinically cardiovascular disease Able to comprehend and sign an informed consent form
- Serious liver dysfunction, defined as AST or ALT \> 3 times the normal upper limit
- Chronic kidney disease (CKD) \> stage 4, defined as eGFR \< 30 ml/min/1.73 m2
- Prior CCTA or invasive coronary angiography within the last 5 years
- Any contraindications for CCTA
- Previous use of statin or non-statin lipid-lowering medication (such as ezetimibe, PCSK9 inhibitor and XueZhiKang)
- Life expectancy \< 3 years
- Other reasons the researcher deems inappropriate to attend
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years to 69 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.